Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLULAVAL) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 4LM54 | — |
received a 2nd Flulaval during the same flu season; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 63-year-old female patient who received Flu Seasonal TIV Quebec (FluLaval 2024-2025 season) (batch number 4LM54, expiry date 30-JUN-2025) for prophylaxis. Previously administered products included Flulaval (received 1st dose on an unknown date). On 07-FEB-2025, the patient received the 2nd dose of FluLaval 2024-2025 season. On 07-FEB-2025, an unknown time after receiving FluLaval 2024-2025 season, the patient experienced extra dose administered (Verbatim: received a 2nd Flulaval during the same flu season). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 10-FEB-2025 The register nurse called and reported that so they had one of our adult patients, received a 2nd Flulaval during the same flu season, so they were wondering what were the typical adverse reactions that could occurred just they could notify the patient which led to extra dose administered. The vaccine administration facility was the same as primary reporter.